Soligenix to Present at BIO Investment & Growth Summit

Soligenix (Nasdaq: SNGX) announced that Christopher J. Schaber, Ph.D., President & CEO, will deliver a corporate presentation at the BIO Investment & Growth Summit on Monday, March 2 at 3:00 PM in Miami Beach, Florida.

Rhea-AI Summary

Soligenix (Nasdaq: SNGX) announced that Christopher J. Schaber, Ph.D., President & CEO, will deliver a corporate presentation at the BIO Investment & Growth Summit on Monday, March 2 at 3:00 PM in Miami Beach, Florida.

Registered attendees may schedule one-on-one meetings via the conference platform; non-attendees can request meetings by emailing ir@soligenix.com. The summit runs March 2–3 at Eden Roc Miami Beach.

Argus Feb 24 session

+4.55% close to close Open Argus

Details

News Market Reaction – SNGX

On Feb 24, the day this news came out, SNGX closed 4.55% above the previous close.

Data tracked by StockTitan Argus for the Feb 24 session.

Market Context

This announcement highlights Soligenix’s participation in the BIO Investment & Growth Summit, offeri...

Analysis

This announcement highlights Soligenix’s participation in the BIO Investment & Growth Summit, offering management an additional venue to communicate its late-stage rare-disease pipeline and strategy. In recent months, the company detailed HyBryte’s confirmatory Phase 3 plans, positive SGX302 and SGX945 data, and capital position through 2026. Investors may watch for new partnership discussions, updates tied to these programs, and any follow-on communications emerging from meetings around the conference.

Key Figures

Presentation time: 3:00 PM Summit dates: March 2–3

Presentation time

3:00 PM

Scheduled BIO Investment & Growth Summit corporate presentation

Summit dates

March 2–3

BIO Investment & Growth Summit held at Eden Roc Miami Beach

Historical Context

5 past events · Latest: Feb 12

5 events

1. Feb 12

   Pipeline and cash update

   24h Move

   -1.9%

   Detailed FLASH2 Phase 3 timing and cash position with reiterated commercial estimates.

2. Dec 18

   Phase 2 data SGX945

   24h Move

   +0.0%

   Publication of positive Phase 2a Behçet’s Disease results showing durable treatment benefit.

3. Dec 17

   SGX302 psoriasis topline

   24h Move

   -19.1%

   Top-line Phase 2a extension data with clinical improvements and good tolerability.

4. Dec 05

   Rare-disease editorial

   24h Move

   -2.4%

   Editorial highlighting Soligenix’s rare-disease focus and HyBryte’s late-stage status.

5. Dec 03

   CTCL platform editorial

   24h Move

   -1.9%

   Editorial on HyBryte as a novel CTCL therapy and company’s late‑stage positioning.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PRINCETON, N.J., Feb. 24, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Christopher J. Schaber, Ph.D., President & Chief Executive Officer will deliver a corporate presentation at the BIO Investment & Growth Summit at 3:00 PM on Monday, March 2. The BIO Investment & Growth Summit, held March 2 to 3 at Eden Roc Miami Beach, in Miami Beach, Florida, will include innovative programs, one-on-one meetings, and company presentations. For more information please refer to the conference website at https://bigs.bio.org/.

Registered conference attendees may schedule a meeting with Soligenix via the conference scheduling platforms. If you are unable to attend the conferences and would like to schedule a meeting with management, please contact ir@soligenix.com.

About Soligenix, Inc.

Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Our Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte™ (SGX301 or synthetic hypericin sodium) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide. Development programs in this business segment also include expansion of synthetic hypericin (SGX302) into psoriasis, our first-in-class innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer, and (SGX945) in Behçet's Disease.

Our Public Health Solutions business segment includes development programs for RiVax^®, our ricin toxin vaccine candidate, as well as our vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax™, our vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2). The development of our vaccine programs incorporates the use of our proprietary heat stabilization platform technology, known as ThermoVax^®. To date, this business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA) and the Biomedical Advanced Research and Development Authority (BARDA).

For further information regarding Soligenix, Inc., please visit the Company's website at https://www.soligenix.com and follow us on LinkedIn and Twitter at @Soligenix_Inc.

This press release may contain forward-looking statements that reflect Soligenix's current expectations about its future results, performance, prospects and opportunities, including but not limited to, potential market sizes, patient populations, clinical trial enrollment. Statements that are not historical facts, such as "anticipates," "estimates," "believes," "hopes," "intends," "plans," "expects," "goal," "may," "suggest," "will," "potential," or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements. Soligenix cannot assure you that it will be able to successfully develop, achieve regulatory approval for or commercialize products based on its technologies, particularly in light of the significant uncertainty inherent in developing therapeutics and vaccines against bioterror threats, conducting preclinical and clinical trials of therapeutics and vaccines, obtaining regulatory approvals and manufacturing therapeutics and vaccines, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further funding to support product development and commercialization efforts, including grants and awards, maintain its existing grants which are subject to performance requirements, enter into any biodefense procurement contracts with the U.S. Government or other countries, that it will be able to compete with larger and better financed competitors in the biotechnology industry, that changes in health care practice, third party reimbursement limitations and Federal and/or state health care reform initiatives will not negatively affect its business, or that the U.S. Congress may not pass any legislation that would provide additional funding for the Project BioShield program. In addition, there can be no assurance as to the timing or success of any of its clinical/preclinical trials. Despite the statistically significant result achieved in the first HyBryte™ (SGX301) Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma or any other studies (including the open-label, investigator-initiated study) and the overall blinded aggregate response rate observed in the second HyBryte™ (SGX301) Phase 3 clinical trial, there can be no assurance that the second HyBryte™ (SGX301) Phase 3 clinical trial will be successful or that a marketing authorization from the FDA or EMA will be granted. Additionally, although the EMA has agreed to the key design components of the second HyBryte™ (SGX301) Phase 3 clinical trial, no assurance can be given that the Company will be able to modify the development path to adequately address the FDA's concerns or that the FDA will not require a longer duration comparative study. Notwithstanding the result in the first HyBryte™ (SGX301) Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma and the Phase 2a clinical trial of SGX302 for the treatment of psoriasis, there can be no assurance as to the timing or success of the clinical trials of SGX302 for the treatment of psoriasis. Additionally, despite the biologic activity observed in aphthous ulcers induced by chemotherapy and radiation, there can be no assurance as to the timing or success of the clinical trials of SGX945 for the treatment of Behçet's Disease. Further, there can be no assurance that RiVax^® will qualify for a biodefense Priority Review Voucher (PRV) or that the prior sales of PRVs will be indicative of any potential sales price for a PRV for RiVax^®. Also, no assurance can be provided that the Company will receive or continue to receive non-dilutive government funding from grants and contracts that have been or may be awarded or for which the Company will apply in the future. These and other risk factors are described from time to time in filings with the Securities and Exchange Commission (the "SEC"), including, but not limited to, Soligenix's reports on Forms 10-Q and 10-K. Unless required by law, Soligenix assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.

View original content to download multimedia:https://www.prnewswire.com/news-releases/soligenix-to-present-at-bio-investment--growth-summit-302695396.html

SOURCE SOLIGENIX, INC.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Soligenix (SNGX) presenting at the BIO Investment & Growth Summit in 2026?

Soligenix (SNGX) will present on Monday, March 2 at 3:00 PM. According to the company, Christopher J. Schaber, Ph.D., President & CEO, will deliver the corporate presentation at Eden Roc Miami Beach during the March 2–3 summit.

Where is the BIO Investment & Growth Summit taking place for Soligenix's (SNGX) presentation?

The summit is held at Eden Roc Miami Beach, Miami Beach, Florida March 2–3. According to the company, the presentation and one-on-one meeting opportunities will be available onsite during the event.

How can investors schedule a meeting with Soligenix (SNGX) at the March 2026 BIO summit?

Registered attendees may schedule meetings via the conference scheduling platforms. According to the company, non-attendees can request meetings by contacting ir@soligenix.com to arrange conversations with management.

Who will present for Soligenix (SNGX) at the BIO Investment & Growth Summit on March 2, 2026?

Christopher J. Schaber, Ph.D., President & CEO, will deliver the presentation. According to the company, he will represent Soligenix during the corporate presentation and available investor meetings at the summit.

Will Soligenix (SNGX) offer one-on-one investor meetings at the March 2–3, 2026 summit?

Yes, one-on-one meetings are available to registered attendees via the conference platform. According to the company, interested investors can also email ir@soligenix.com to request meetings if unable to attend.

Where can I find more information about the BIO Investment & Growth Summit where Soligenix (SNGX) will present?

Event details and schedules are available on the summit website at the event's official page. According to the company, the conference website provides registration, agenda, and scheduling tools for attendees.